The conformity route begins with intended use and risk classification. A quality system certificate, clinical evaluation or registration alone does not complete the entire CE process.
Determine how the device is marketed and each party's MDR role. Own-brand supply may create manufacturer duties; assess specific contractual arrangements against the relevant provisions. Clarify technical file access, quality systems and post-market responsibilities. Do not treat the factory's certificate as transferring all your duties.
Assess classification alongside sterility, measuring functions and reusable surgical instrument characteristics. Some Class I devices need body involvement limited to specific aspects. Self-declaration routes still require technical documentation and other obligations. Classification should not be determined from the product name alone.
Explain relevance to intended use and technical and biological characteristics. Assess equivalence conditions and data access; use for the same disease alone is insufficient. Develop a device-specific clinical evaluation and additional-data plan. Do not assume clinical investigation is universally required or universally unnecessary.
Assess effects of the new site, method or process on sterility and device characteristics. Review validation, packaging, shelf life and biological safety as needed. Follow the relevant notified body's change and notification rules. The same service name does not establish coverage by earlier evidence.
Review effects on intended use, clinical decisions, performance and risks. An interface correction differs from adding a diagnostic function. Update verification, risk and clinical evidence where needed and make required notifications. A minor version-number change does not establish a minor regulatory effect.
Assess the event, potential harm, recurrence and affected devices promptly. Consider MDR vigilance, reporting and field safety duties under their specific conditions and deadlines. Complaints do not all lead to identical actions, but required reporting should not wait for a definitive cause. Keep decisions and follow-up traceable.
Share the subject, organisation or product, target market, current evidence and target date. The team can then separate consultancy, official fees, independent evaluation and realistic timing.
TRTürkçe
ENEnglish
AZAzərbaycanca
UZO‘zbekcha
ARالعربية
FRFrançais
DEDeutsch
RUРусский